Latest Conference Articles

In this interview at SDPA, Scherer provides an overview of foot web space infections, fungal versus bacterial infections, and more.

At SDPA 2025, Cotter highlights clinical patterns in alopecia areata that may respond better, or worse, to JAK inhibition and shares his approach to systemic therapy.

Attar discusses the medication pipeline, possible AI implementation, and the importance of making patients aware of clinical trials for rare genetic diseases.

This presentation, covered at SDPA, features a discussion by Ginette Okoye, MD, who highlights diagnostic challenges among even experienced clinicians.

Lang discusses his expectations and excitement for upcoming developments in the field and encourages clinicians to work together to better treat complex patients.

At SDPA 2025, Mangin emphasized the importance of wood lamp use, JAK inhibitors, and phototherapy in managing vitiligo and preventing relapse.

Hope Cook, PA-C, speaks in this interview at SDPA about strategies for clinicians seeking to overcome burnout in their careers.

At SDPA 2025, Mangin discussed her vitiligo approach, misconceptions, and how to determine when the disease is active.

In this interview at SDPA 2025, Hope Cook, PA-C, describes the contents of her talk regarding helping clinicians heal from burnout.

Brimer sat down with HCPLive to discuss her presentation of a study analyzing the refill rates of PFHO and common alternative cyclosporine ophthalmic emulsion .05%.

In this segment of her SDPA interview, Orit Markowitz, MD, highlights several points about dermoscopy, including common issues with identifying benign lesions.

More than 60% of patients with psoriasis achieved PASI 100 at week 16 with bimekizumab and maintained skin clearance up to 4 Years.

The topics of different hair textures and the management of alopecia in patients with skin of color were highlighted by Ginette Okoye, MD, at SDPA 2025.

Orit Markowitz, MD, highlighted takeaways from her SDPA presentation on the recognition of benign patterns in dermoscopy.

A recent post hoc analysis of 2 pivotal phase 3 trials has determined the efficacy of acoltremon .003% in reducing ocular surface damage in dry eye disease.

From uncovering new benefits of semaglutide to targeting hypercortisolism in people with type 2 diabetes, here are 5 key updates from the annual meeting.

Nearchou discusses the implications for early detection of specific learning disabilities and the potential for early intervention to provide equal access to education.

This interview at SDPA features Janelle Ball, founder and CEO of BC Educators, who discusses tips related to success with insurance authorizations.

Amlitelimab shows promise as a safe and effective treatment for moderate-to-severe atopic dermatitis, with sustained benefits post-treatment.

This interview segment at the 2025 SDPA Conference highlights additional insights by Friedman on the management and diagnosis of chronic hand eczema, or CHE.

Based on recent data, artificial intelligence can improve patients’ awareness of their condition, as well as confidence in, and satisfaction with, their care.

In an interview conducted at the 2025 SDPA Conference, Friedman provided several insights into management and diagnosis of chronic hand eczema, or CHE.

At SDPA 2025, Candrice Heath, MD, said many clinicians remain unaware of baby perfume traditions that may contribute to persistent symptoms in patients of color.

Research has indicated a substantial increase in axial length, a contributing factor of myopia, in young adults who report regular mobile device usage.

At SDPA 2025, Candrice Heath, MD, presented on what you can do in your clinic to bridge the gap in pediatric atopic dermatitis among children with darker skin tones.

This session with Ginette Okoye, MD, features a discussion about hidradenitis suppurativa (HS) and several helpful approaches for patients.

Verma discussed how recent advances in the field affect clinician management of type 2 diabetes and peripheral artery disease.